Posted by Michael Wonder on 20 May 2017
Brodalumab, a novel biologic for people with moderate-to-severe psoriasis, receives positive opinion from European CHMP
18 May 2017 - LEO Pharma today announced that it received a positive opinion from the European CHMP recommending marketing authorisation for brodalumab, a novel biologic treatment for adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Brodalumab is the only fully human monoclonal antibody that selectively targets the IL-17 receptor subunit A By binding to the receptor with high affinity, brodalumab effectively blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are important in psoriasis.
